Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system). The partnership reflects both companies’ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.
Integrating these two products will enable healthcare professionals, caregivers and people with diabetes to view glucose and insulin data together to help them make more informed treatment decisions and to have a more meaningful and productive conversation about health outcomes.
“Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors,” said Anders Dyhr Toft, corporate vice president, Commercial Innovation, Novo Nordisk. “Together with partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient’s individual diabetes management and can help people with diabetes feel more confident in their treatment.”
“It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes,” said Jared Watkin, senior vice president, Diabetes Care, Abbott. “Diabetes is a time-intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake. By enabling insulin dosing data from Novo Nordisk’s connected pens to be shared with our digital health tools, we’ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life.”
Abbott and Novo Nordisk are working hard to bring these integrated solutions to patients as soon as possible.